Bibliography
- Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2006;2:80-91
- Lee W, Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004;44:137-66
- Launay-Vacher V, Izzedine H, Karie S, Renal tubular drug transporters. Nephron Physiol 2006;103:97-106
- Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician 2008;78:743-50
- Taber SS, Pasko DA. The epidemiology of drug-induced disorders: the kidney. Expert Opin Drug Saf 2008;7:679-90
- Uchino S, Kellum JA, Bellomo R, Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005;294:813-18
- Gurwitz JH, Field TS, Harrold LR, Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289:1107-16
- Vaidya VS, Waikar SS, Ferguson MA, Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci 2008;1:200-8
- RIFLE Criteria for Acute Renal Dysfunction. Available from: http://www.medicalcriteria.com/criteria/neph_rifle.htm [Last accessed xxxx]
- Mehta RL, Kellum JA, Shah SV, Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31
- Bagshaw SM, George C, Bellomo R; ANZICS Database Management Committee. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008;23:1569-74
- Siew ED, Matheny ME, Ikizler TA, Commonly used surrogates for baseline renal function affect the classification and prognosis of acute kidney injury. Kidney Int 2010;77:536-42
- Zavada J, Hoste E, Cartin-Ceba R, AKI6 investigators. A comparison of three methods to estimate baseline creatinine for RIFLE classification. Nephrol Dial Transplant 2010;25:3911-18
- Zappitelli M, Moffett BS, Hyder A, Goldstein SL. Acute kidney injury in non-critically ill children treated with aminoglycoside antibiotics in a tertiary healthcare centre: a retrospective cohort study. Nephrol Dial Transplant 2011;26:144-50
- Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta 2005;351:31-47
- Mishra J, Dent C, Tarabishi R, Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365:1231-8
- Dieterle F, Sistare F, Goodsaid F, Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol 2010;28:455-62
- Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006;70:2021-30
- Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008;8:117
- Coresh J, Selvin E, Stevens LA, Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47
- Ponte B, Felipe C, Muriel A, Long-term functional evolution after an acute kidney injury: a 10-year study. Nephrol Dial Transplant 2008;23:3859-66
- Bates DW, Su L, Yu DT, Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-93
- Tostivint I, du Montcel ST, Jaudon MC, Renal outcome after ciclosporin-induced nephrotoxicity. Nephrol Dial Transplant 2007;22:880-5
- Schwarz A, Krause P-H, Kunzendorf U, The outcome of acute interstitial nephritis : risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 2000;54:179-90
- NKF/KDOQI Definition and classification of stages of chronic kidney disease. Available from: http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p4_class_g1.htm [Last accessed 15 March 2012]
- Hallan SI, Ritz E, Lydersen S, Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009;20:1069-77
- Levey AS, Stevens LA, Schmid CH, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12
- Stevens LA, Schmid CH, Greene T, Comparative Performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study Equations for Estimating GFR Levels Above 60 mL/min/1.73 m2.. Am J Kidney Dis 2010;56:486-95
- John R, Herzenberg AM. Renal toxicity of therapeutic drugs. J Clin Pathol 2009;62:505-15
- Anglicheau D, Pallet N, Rabant M, Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006;70:1019-25
- Zimmermann AE, Pizzoferrato T, Bedford J, Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006;42:283-90
- Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008;74:158-69
- Final Conlusions on the Pilot Joint EMEA/FDA VXDS Experience on the Qualification of Nephrotoxicity Biomarkers. Committee for Medicinal Products for Human Use. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004205.pdf [Last accessed 12 September 2011]
- Qualification opinion ILSI/HESI submission of novel renal biomarkers of toxicity. Committee for Medicinal Products for Human Use. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/11/WC500099359.pdf [Last accessed 12 September 2011]
- Leblanc M, Kellum JA, Gibney RT, Risk factors for acute renal failure: inherent and modifiable risks. Curr Opin Crit Care 2005;11:533-6
- Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol 2009;4:1275-83
- HESI Committee on Biomarkers of Nephrotoxicity. Available from: http://www.hesiglobal.org/i4a/pages/index.cfm?pageID=3541 [Last accessed 12 September 2011]
- Christensson A, Solve Elmstahl S. Estimation of the age-dependent decline of glomerular filtration rate from formulas based on creatinine and cystatin C in the general elderly population. Nephron Clin Pract 2011;117:c40-50
- Pediatric Expertise for Advisory Panels; Guidance for Industry and FDA Staff. 2003. Available from: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm082185.htm [Last accessed 9 March 2012]
- Bokenkamp A, Domanetzki M, Zinck R, Cystatin C- a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 1998;101:875-81
- Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf [Last accessed 12 September 2011]
- Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies in vitro. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072104.pdf [Last accessed 12 September 2011]
- Note for Guidance on the Investigation of Drug Interactions. Committee for Proprietary Medicinal Products (CPMP). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002966.pdf [Last accessed 12 September 2011]
- Kiortsis DN, Filippatos TD, Mikhailidis DP, Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2007;195:7-16
- Verhulst A, D'Haese PC, De Broe ME. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004;15:2249-57
- Bonventre JV, vaidya VS, schmarder R Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010;28(5):436-40
- Devarajan P. The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis 2010;17(6):469-79; PMID 21044769
- Available from: http://www.fda.gov/ScienceResearch/CollaborativeOpportunities/CooperativeResearchandDevelopmentAgreementsCRADAs/ucm122820.htm [Last accessed 9 March 2012]
- Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005;365:417-30